Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma.

A 26-year-old man with limited-stage classic Hodgkin lymphoma (cHL) achieved complete response after standard treatment with combined modality treatment of involved-field radiation and four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Fourteen years later, enlarged mediastinal lymph nodes were revealed by computed tomography, and based on identical histological findings, he was diagnosed with cHL, considered to be a recurrence of the initial disease. HL is a rare subtype of malignant lymphoma in Japan, and there are limited data on well-documented cases in Japanese, especially very late recurrence. Our case has shown that CR could be achieved again with the use of brentuximab vedotin (BV) followed by autologous stem cell transplantation (ASCT) for such late recurrence. Although the possible risk factors for relapse of cHL remain uncertain, patients with late-relapse cHL that occurs 5 or more years after the end of initial therapy show better survival after additional treatment than that in patients with early-relapse cHL. Due to the possible occurrence of very late relapse, as described in the present case report, a reconsideration of strategies for long-term follow-up after chemoradiotherapy for limited-stage cHL is warranted. © The Japan Society of Clinical Oncology 2021.